Bruno Silva-Santos
Overview
Explore the profile of Bruno Silva-Santos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
117
Citations
5745
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Inacio D, Amado T, Pamplona A, Sobral D, Cunha C, Santos R, et al.
Nat Immunol
. 2025 Jan;
26(3):497-510.
PMID: 39881001
γδ T cells producing either interleukin-17A (γδ cells) or interferon-γ (γδ cells) are generated in the mouse thymus, but the molecular regulators of their peripheral functions are not fully characterized....
2.
Souza Dos-Santos J, Firmino-Cruz L, Oliveira-Maciel D, da Fonseca-Martins A, Ramos T, Nunes-Sousa L, et al.
J Leukoc Biol
. 2024 Dec;
PMID: 39656754
γδ T cells play diverse roles in immune responses, producing either IL-17A or IFN-γ. Here we investigated the impact of this functional dichotomy on cutaneous leishmaniasis. We demonstrate that in...
3.
Blanco-Dominguez R, Mensurado S, Barros L, Carreira M, Silva-Santos B
Methods Cell Biol
. 2024 Nov;
190:119-132.
PMID: 39515876
Colorectal cancer (CRC) presents a substantial global health challenge, prompting the necessity for the development and validation of preclinical models to enhance our comprehension and therapeutic interventions. Among the myriad...
4.
Mensurado S, Blanco-Dominguez R, Carreira M, Barros L, Silva-Santos B
Methods Cell Biol
. 2024 Nov;
190:105-117.
PMID: 39515874
Colorectal cancer (CRC) research demands reliable experimental models to enhance translational potential. Immortalized cancer cell lines, although commonly employed, exhibit limitations such as phenotypic divergence from primary tumors, which underscores...
5.
Hayday A, Dechanet-Merville J, Rossjohn J, Silva-Santos B
Science
. 2024 Oct;
386(6717):eabq7248.
PMID: 39361750
The premise of cancer immunotherapy is that cancers are specifically visible to an immune system tolerized to healthy self. The promise of cancer immunotherapy is that immune effector mechanisms and...
6.
Lobo-Martins S, Corredeira P, Cavaco A, Rodrigues C, Piairo P, Lopes C, et al.
Cells
. 2024 Aug;
13(16).
PMID: 39195280
The combination of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) with endocrine therapy (ET) is the standard-of-care for estrogen receptor (ER)-positive, HER2-negative (ER+/HER2- advanced/metastatic breast cancer (mBC). However, the impact of CDK4/6i...
7.
Sumaria N, Fiala G, Inacio D, Curado-Avelar M, Cachucho A, Pinheiro R, et al.
Nat Immunol
. 2024 May;
25(7):1207-1217.
PMID: 38802512
The contribution of γδ T cells to immune responses is associated with rapid secretion of interferon-γ (IFN-γ). Here, we show a perinatal thymic wave of innate IFN-γ-producing γδ T cells...
8.
Mensurado S, Condeco C, Sanchez-Martinez D, Shirley S, Coelho R, Tirado N, et al.
Blood
. 2024 Mar;
143(15):1488-1495.
PMID: 38437507
Relapsed or refractory acute myeloid leukemia (AML) remains a major therapeutic challenge. We have recently developed a Vδ1+ γδ T cell-based product for adoptive immunotherapy, named Delta One T (DOT)...
9.
Costa G, Mensurado S, Silva-Santos B
J Immunother Cancer
. 2023 Nov;
11(11).
PMID: 38007241
γδ T cells are regarded as promising effector lymphocytes for next-generation cancer immunotherapies. In spite of being relatively rare in human peripheral blood, γδ T cells are more abundant in...
10.
Silva-Santos B, Ribot J, Adams E, Willcox B, Eberl M
Nat Immunol
. 2023 Sep;
24(10):1606-1609.
PMID: 37749327
No abstract available.